Risk profile and outcome in Hodgkin's lymphoma: is obesity beneficial?
Open Access
- 31 March 2005
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 16 (5) , 838-840
- https://doi.org/10.1093/annonc/mdi145
Abstract
Great advances have been made in oncology with regard to diagnostics, prognostics and therapeutics. However, dosing of chemotherapy in most cancers is still being based on the estimation of body surface area (BSA) [log (body surface in m2)=0.425 log (weight in kg) + 0.725 log (length in cm)+ 1.8564]. BSA fails, however, to standardize the marked inter-patient variation in pharmacokinetics for most cytotoxic drugs [1]. If not adjusted for, overweight and obese individuals receive higher relative (to tumor burden) doses of chemotherapy compared with normal or underweight individuals.This publication has 4 references indexed in Scilit:
- Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experienceAnnals of Oncology, 2004
- Influence of body mass index on outcomes and treatment‐related toxicity in patients with colon carcinomaCancer, 2003
- Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograftBone Marrow Transplantation, 2000
- Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.Journal of Clinical Oncology, 1996